Physician profile
Christopher Neumann
NPI 1306051479
$1,068.92
in general payments reported to CMS, 2019-2025
23 companies · $188 in 2025
The $188 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $239 · 2020: $100 · 2021: $187 · 2022: $98.39 · 2023: $105 · 2024: $150 · 2025: $188.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $313.10 | 2019-2024 | Wavewriter Alpha Prime 16 |
| Medtronic, INC. | $95.10 | 2023-2025 | Kyphon Express II Kyphopak Tray, Intellis Adaptivestim |
| Surgalign Spine Technologies, INC. | $88.83 | 2021 | |
| Globus Medical, INC. | $78.14 | 2019 | |
| Xtant Medical INC | $61.16 | 2024 | |
| Amneal Pharmaceuticals LLC | $60.13 | 2021-2024 | Rytary |
| Neurocrine Biosciences, INC. | $52.78 | 2022-2023 | Ongentys, Ingrezza |
| Lilly USA, LLC | $43.59 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $32.01 | 2023-2025 | Soliris, Ultomiris |
| Abbott Laboratories | $27.87 | 2019-2020 | |
| Zimvie INC. | $25.89 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.81 | 2025 | Inbrija |
| Abbvie INC. | $22.65 | 2025 | |
| Lundbeck LLC | $20.82 | 2025 | Vyepti |
| Ucb, INC. | $16.87 | 2025 | Fintepla |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $16.41 | 2022 | |
| Pfizer INC. | $15.32 | 2025 | |
| Adamas Pharmaceuticals, INC. | $14.50 | 2021 | |
| Biogen, INC. | $13.15 | 2023 | Vumerity |
| Greenwich Biosciences, INC. | $12.28 | 2021 | |
| Baxter Healthcare | $12.14 | 2019 | |
| Aprecia Pharmaceuticals, LLC | $11.71 | 2021 | |
| Csl Behring | $11.66 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Neumann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.